- Clinical Evaluation -
We transform ideas into safe, effective, and approved medical solutions.
Eliminate once and for all the risk of rejections and requirements hindering your business at ANVISA (Brazilian Health Regulatory Agency). DMH GROUP protects the regulatory strategy of your medical device through the practical experience of specialists with over 15 years of real-world experience , guaranteeing clinical reports without rework.
Speak to a specialist.
The Cost of Uncertainty vs. Real Return with DMH Group
Every day your medical device is held up by ANVISA represents frozen working capital and market share handed directly to your competition.
Maximizing ROI
Accelerate your Go-to-Market by drastically reducing dossier preparation time. Your device starts generating revenue in the shortest feasible time.
Defense by Meta-analysis
We combine statistics and clinical data from the literature under strict scientific rigor. A true shield against the scrutiny of regulatory inspectors.
ANVISA Guide No. 31/2020
A surgical demonstration of equivalence that eliminates blind spots in the dossier submission. Exactly as required by the health agency.
Real Predictability
Allow your sales team to plan sales and contracts with predictable dates, without surprises along the way.
The Absolute Security of Hiring Senior Healthcare Professionals
+15 Years
Direct Practice
We don't delegate your most valuable asset to junior professionals. Our leading experts design technical solutions that avoid the back-and-forth of undue demands.
Alignment with ISO 14155: Structured compliance under international best practices in clinical research, generating highly acceptable reports.
Dynamic Risk Connection (RDC 751/2022): The clinical report is not an isolated piece. It is born integrated with your Risk Management and your PMCF (Post-Market Follow-up) plan.
International Passport: Structured reports designed to serve as a strong technical and regulatory foundation, also for commercial expansion into Latin America and Europe.
Senior consultants who have in-depth knowledge of regulatory and market nuances.
Zero
Theoretical Bottleneck
Surgical strategy for direct approval, saving time and money in the laboratory.
Sustainability
Operational
To protect the brand's reputation and ensure the long-term viability of its product portfolio.
We don't just deliver technical reports.
DMH GROUP's regulatory consulting division combines the highest international scientific rigor with the experience of those who master ANVISA's requirements and market expansion strategies for healthcare throughout Latin America. We guarantee the compliance of your operation from start to finish.
Start your
planning
successful
Fill out the form to schedule an initial strategic clinical assessment diagnosis for your medical device .